BHC's core business is beating expectations and expanding abroad
Q2 earnings blow past estimates, guidance raised BHC reported Q2 adjusted earnings of $1.26 per share, far above the 96-cent estimate, on revenue up 13% to $2.85 billion. It raised full-year 2026 revenue and profit guidance. Strong results make the company look healthier and more valuable, pushing the stock up sharply.
This is the single biggest new force behind BHC's move, directly driving the 28% share surge.
Salix and Solta drive the growth The Salix stomach-drug business grew 21%, with Xifaxan up 26%, and Solta Medical aesthetics jumped 38%. These fast-growing segments are the engine of BHC's results, showing its core products still have strong demand and can keep lifting profit.
Explains which parts of the business are actually powering the earnings beat, not just the headline number.
PrOKEDI added to Quebec's public drug list BHC's schizophrenia drug PrOKEDI was listed on Quebec's RAMQ formulary, meaning the province's public health plan will now pay for it. This is a step toward real sales in Canada and shows the company can win reimbursement for new products.
A concrete regulatory win that opens a new paying market for a BHC product.
Skincare partnership expands into new markets BHC extended its YUN probiotic skincare deal into Mexico and five more Central/Eastern European and Central Asian markets, adding to the original Poland launch. More countries mean more product sales and a wider dermatology footprint, though this segment is currently flat.
Shows a new international growth avenue, but one that is still small relative to the core earnings story.